Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

Share Price is delayed by 15 minutes
Get Live Data
66.50    -0.10 (-0.15%)
Bid:
66.00
Ask:
67.00
Spread: 1.00 (1.515%)
Market Cap: £80.63m
VLG Live PriceLast checked at - London Stock Exchange

Intraday Venture Life Share Chart

30-year exclusive distribution deal signed

26 Jan 2015 07:00

RNS Number : 0861D
Venture Life Group PLC
26 January 2015
 



26 January 2015

 

Venture Life Group plc

 

("Venture Life" or "the Group")

 

30-year exclusive distribution deal with major skincare and cosmetics retailer in China

 

Venture Life Group plc (AIM: VLG), the international consumer products group addressing the self-care needs of the ageing population, announces that it has signed an exclusive 30-year distribution deal with one of the largest skincare and cosmetics retail chains in China.

 

The agreement is with REC Cosmetics (Shanghai) Limited ("REC"), a subsidiary of Gialen Group Co. Ltd ("Gialen"). Gialen is a privately owned business with 10,000 employees operating in over 1,000 of its own retail skincare and cosmetics stores across mainland China. Gialen is currently undertaking a rapid new store opening programme and over 300,000 customers currently visit their stores daily.

 

Under the terms of the distribution agreement, REC has the exclusive right to sell an initial range of 15 skincare products, including some products from Venture Life's anti-ageing range, ("the Initial Range") in China, Macau, Hong Kong and Taiwan. Venture Life will be the exclusive manufacturer and supplier to REC for all current and any future products under the agreement.

 

The Initial Range is expected to be launched in Gialen Group stores in China in the second half of 2015, subject to registration approval. For the Initial Range, contractual annual minimum purchase obligations ("MPO") have been agreed, the achievement of which maintains REC's rights to distribute the products. The MPO are worth approximately RMB 52.8m (£5.7m)* in sales for Venture Life over the first five years after product registration, including RMB 8.5m (£0.9m)* during the first year after registration. Over the full term of the agreement, the total MPO are worth approximately RMB 371m/£40m* in sales for Venture Life.

 

Jerry Randall, Chief Executive Officer of Venture Life, commented:

 

"We are delighted to have signed a very significant deal with such a progressive, fast-growing Chinese skincare and cosmetics business. We have worked through a very detailed process to arrive at this agreement with a partner who clearly shares our philosophy, ethos and ambition to grow in China.

 

"This agreement demonstrates there is a strong appetite for our products in China and the other territories, where the demand for high quality Western products, particularly in skincare, remains strong. Our Italian manufacturing capacity and capability has also been a major factor in securing this agreement, and further validates our strategic approach as an integrated product development, manufacturing and commercialisation company. We expect this deal to represent just the start of a very successful collaboration with Gialen in China."

 

* At current exchange rates as the Initial Range is priced in RMB.

- Ends -

 

For further information please contact:

Venture Life Group PLC

Jerry Randall, Chief Executive Officer

James Hunter, Chief Financial Officer +44 (0) 1344 742 870

 

Panmure Gordon (UK) Limited Freddy Crossley / Duncan Monteith +44 (0) 20 7886 2500Corporate Finance

Tom SalvesenCorporate Broking

 

Square1 Consulting

David Bick

Mark Longson +44 (0) 20 7929 5599

 

Notes to editors

 

About Venture Life

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product range and pipeline currently include food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin. The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.

 

Through its manufacturing company, Biokosmes, the Group also provides development and manufacturing services to companies in the medical device and cosmetic sectors.

The Group's own branded products are currently sold or partnered in over 40 countries and currently include:

· food supplements to maintain brain function and memory;

· dermo-cosmetics for addressing the signs of skin ageing and hair loss, and

· medical devices for improving conditions such as minor aches and pains, dry eyes and itchy skin.

 

The Company has a healthy development pipeline including products in areas such as diabetes, cardiovascular health, obesity, cognitive function and skin ageing. Products coming from the pipeline will be expected to have intellectual property protection and be supported by independent clinical evidence of efficacy.

 

About Gialen

Gialen was founded in 2005 and is headquartered in Guangzhou, China. Gialen is one of the largest cosmetics retail chains in China with over 1,000 stores and 300,000 customers daily.

 

Gialen sells an extensive range of products, listing some of the world's best known skincare, cosmetics and personal-care brands including L'Oreal, Shiseido, Olay and Nivea.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRBAMBTMBMTTAA
Date   Source Headline
9th Dec 20257:00 amRNSSale of Non-Core Products
8th Dec 20257:00 amRNSTransaction in Own Shares
2nd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20254:30 pmRNSTotal Voting Rights
1st Dec 20257:00 amRNSTransaction in Own Shares
28th Nov 20257:00 amRNSTransaction in Own Shares
25th Nov 20257:00 amRNSTransaction in Own Shares
21st Nov 20257:00 amRNSTransaction in Own Shares
20th Nov 20257:00 amRNSTransaction in Own Shares
19th Nov 20257:00 amRNSTransaction in Own Shares
18th Nov 20257:00 amRNSTransaction in Own Shares
3rd Oct 20254:40 pmRNSDirector/PDMR Shareholding
30th Sep 20257:01 amRNSShare Buyback Programme
30th Sep 20257:00 amRNSInterim Results
29th Sep 202512:19 pmRNSInvestor Presentation via Investor Meet Company
24th Sep 20252:38 pmRNSChange of Accounting Reference Date
8th Sep 20257:00 amRNSDirectorate Change
19th Aug 20252:04 pmRNSHolding(s) in Company
5th Aug 20253:43 pmRNSResult of General Meeting
25th Jul 20257:05 amRNSGrant of Share Options
25th Jul 20257:00 amRNSCompletion of Divestment & Trading Update
7th Jul 20254:21 pmRNSDirector/PDMR Shareholding
3rd Jul 20257:00 amRNSDirector Dealings
2nd Jul 20257:00 amRNSNotice of General Meeting & Investor Presentation
1st Jul 20254:08 pmRNSHolding(s) in Company
30th Jun 20253:15 pmRNSResult of AGM
30th Jun 20253:13 pmRNSFinal Results for year ended 31 December 2024
5th Jun 20252:19 pmRNSNotice of Annual General Meeting
19th May 20257:01 amRNSDirector Dealings
19th May 20257:00 amRNSBoard Update
12th May 20258:49 amRNSReplacement: Cash sale of CDMO operations
12th May 20257:00 amRNSCash sale of CDMO operations
28th Apr 202510:50 amRNSHolding(s) in Company
8th Apr 20254:53 pmRNSHolding(s) in Company
20th Feb 20251:14 pmRNSHolding(s) in Company
18th Feb 202510:02 amRNSHolding(s) in Company
4th Feb 20257:01 amRNSBoard Changes
4th Feb 20257:00 amRNSTrading Statement
21st Jan 20258:15 amRNSExercise of Share Options & Total Voting Rights
20th Jan 202511:49 amRNSHolding(s) in Company
19th Dec 202411:48 amRNSHolding(s) in Company
4th Nov 20243:44 pmRNSHolding(s) in Company
30th Oct 202412:01 pmRNSDirector/PDMR Shareholding
30th Oct 202410:58 amRNSDirector/PDMR Shareholding
30th Oct 20247:00 amRNSAcquisition of Health & Her Limited
1st Oct 202412:47 pmRNSHolding(s) in Company
30th Sep 20247:00 amRNSInterim Results
26th Sep 20247:00 amRNSInvestor Presentation via Investor Meet Company
2nd Sep 202410:41 amRNSDirector/PDMR Shareholding
2nd Sep 202410:40 amRNSReplacement - Exercise of Options & TVR

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.